Taccetti Giovanni

Taccetti Giovanni

INSTITUTE

Azienda Ospedaliero Universitaria Meyer

Email

g.taccetti@meyer.it

ADDRESS

Dipartimento di Medicina Pediatrica, Centro Fibrosi Cistica – Viale Pieraccini 24, Firenze

PHONE

055 5662474 – Fax 055 5662474

Developed skills and lines of research

Giovanni Taccetti obtained his degree in Medicine from the University of Florence in 1983. In 1988, at the same university, he obtained a specialization in Pediatrics. Today he works at the Meyer Hospital in Florence at the Cystic Fibrosis Center, where he is responsible for assistance and coordinates the Microbiology and Research Laboratory Sector, with particular reference to the integration between clinical activities and those of the Microbiology Laboratory, including research programs. Since 1998, he has been a principal investigator or partner in many research projects in the field of cystic fibrosis: he has been and is particularly involved in molecular epidemiology of Pseudomonas aeruginosa and Burkholderia cepacia bacteria in CF patients, development of diagnostic tests to isolate species of B. cepacia complex, a clinical trial on the treatment of methicillin-resistant Staphylococcus aureus (MRSA), analysis of the microbiome (entire community of bacteria colonizing the lung) to understand the risk of respiratory worsening and personalize antibacterial therapy in CF.

Projects funded by FFC Ricerca as Principal Investigator or as Research Manager

FFC#30/2015
Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways

FFC#20/2012
Early antibiotic treatment for MRSA eradication in cystic fibrosis patients: a randomised multicentre study

FFC#17/2007
Early antibiotic treatment in Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols

FFC#18/2004
Early eradication of P. Aeruginosa and subsequent colonization in Cystic Fibrosis patients


Projects financed by FFC Ricerca as a partner

FFC#8/2012
Investigation of cystic fibrosis airway microbiome in patients showing a severe decline in lung function and not responding to conventional antimicrobial therapy

FFC#10/2014
Investigating the airway microbiome in cystic fibrosis patients with a severe decline in lung function: an opportunity for a personalized microbiomebased therapy

FFC#9/2003
Development of a rapid diagnostic test to discriminate B. cepacia complex species and genomovars in routine clinical analysis involving CF patients

Publications from FFC Research projects

Taccetti G, Campana S, Festini F et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005 Sep;26(3):458-61. 

Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012 Oct;67(10):853-9. Epub 2012 Feb 29.

Dolce D, Cariani L, Campana S, et al. Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients. J Cyst Fibros, 2014 Jan;13(1):116-7. doi: 10.1016/j.jcf.2013.08.003. Epub 2013 Sep 7.

Dolce D, Neri S, Grisotto L, et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS One. 2019 Mar 22;14(3):e0213497. doi: 10.1371/journal.pone.0213497. eCollection 2019.

Giovanni Taccetti, Daniela Dolce, Silvia Campana, Novella Ravenni, Michela Francalanci, Gianfranco Mergni, Tommaso Orioli, Lucia Zavataro, Cesare Braggion, Giuseppe Tuccio, Carla Colombo, Lisa Cariani, Daniela Girelli, Mirella Collura, Maria Antonietta Orlando, Giovanna Pisi, Maria Luisa Villani, Francesco Longo. Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14 (Suppl 1):5